A population-based, descriptive analysis of malignant intraductal papillary mucinous neoplasms of the pancreas

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 10, 2008, Pages 2737-2741

  Le, Hoa ^a   Ziogas, Argyrios ^a,b   Rhee, Jessica M ^a   Lee, John G ^b   Lipkin, Steven M ^a,b   Zell, Jason A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DETERMINATION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; ENDOCRINE TUMOR; FEMALE; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIAL STATUS; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA, MUCINOUS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CALIFORNIA; CARCINOMA, PANCREATIC DUCTAL; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS;

EID: 54249151585     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0417     Document Type: Article

References (24)

1. Howe HL, Wu XC, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among US Hispanic/Latino populations. Cancer 2006;107:1711-42.
2. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280:1747-51.
3. Reber HA, Gloor B. Radical pancreatectomy. Surg Oncol Clin N Am 1998;7:157-63.
4. Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C. Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 2004;16:265-74.
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
6. Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev 2007;16:546-52.
7. Furukawa T, Takahashi T, Kobari M, Matsuno S. The mucus-hypersecreting tumor of the pancreas - development and extension visualized by 3-dimensional computerized mapping. Cancer 1992;70:1505-13.
8. Sessa F, Solcia E, Capella C, et al. Intraductal papillary-mucinous tumors represent a distinct group of pancreatic neoplasms - an investigation of tumor-cell differentiation and K-Ras, P53 and C-Erbb-2 abnormalities in 26 patients. Virchows Arch 1994;425:357-67.
9. Milchgrub S, Campuzano M, Casillas J, Alboressaavedra J. Intraductal carcinoma of the pancreas. Cancer 1992;69:651-6.
10. Nagai E, Ueki T, Chijiiwa K, Tanaka M, Tsuneyoshi M. Intraductal papillary mucinous neoplasms of the pancreas associated with so-called mucinous ductal ectasia - histochemical and immunohistochemical analysis of 29 cases. Am J Surg Pathol 1995;19:576-89.
11. Tanaka M, Kobayashi K, Mizumoto K, Yamaguchi K. Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol 2005;40:669-75.
12. Yamada M, Kozuka S, Yamao K, Nakazawa S, Naitoh Y, Tsukamoto Y. Mucin-producing tumor of the pancreas. Cancer 1991;68:159-68.
13. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002;123:1500-7.
14. Parikh-Patel A, Bates JH, Campleman S. Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988-2000. Cancer 2006;107:1189-95.
15. Cancer reporting in California: standards for automated reporting. California cancer reporting system standards, volume II: California Department of Health Services, Cancer Surveillance Section, Sacramento CA, 1997.
16. Cancer reporting in California: data standards for regional registries and California cancer registry. California cancer reporting standards, volume III: California Department of Health Services, Cancer Surveillance Section, Sacramento CA, 1997.
17. Seiffert JE, Price WT, Gordon B. The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 1990;11:59-73.
18. How complete are California Cancer Registry data? From the California Cancer Registry website: http://www.ccrcal.org/questions.html. 2007.
19. Tucker T, Howe H, Weir H. Certification for population-based cancer registries. J Registry Manage 1999;26:24-7.
20. Fritz A, Percy C, Jack A, Shanmugaratnam K, Parkin DM, Whelan S. International classification of diseases for oncology. 3rd ed. Geneva: WHO: 2000.
21. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 2001;12:703-11.
22. ICD-9-CM: international classification of diseases, 9th revision, clinical modification, fifth edition, color coded, volumes 1,2, and 3. Los Angeles: Practice Management Information Corp., 1997.
23. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
24. Lipkin SM, Rhee JM, Zell JA, Iwata K, Meyskens FL. Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms. AACR International Conference on Frontiers in Cancer Prevention Research, Boston MA, Nov.12-15, 2006.